Rare Diseases And The Integrated CDMO Support System

By David O’Connell, Director of Scientific and Technical Affairs

Rare disease drug development operates in a world where scientific precision, operational discipline, and global coordination matter far more than scale. This article explores how the unique realities of rare diseases — small, geographically dispersed patient populations, highly targeted and often potent molecules, and compressed development timelines — demand a fundamentally different support model. With more than 7000 recognised rare diseases and fewer than 5% having an approved treatment, each programme carries outsized importance, where a single batch or shipment can meaningfully influence clinical progress.

The discussion highlights how modern CDMOs are evolving to meet these needs through low‑volume, high‑mix manufacturing, advanced containment for potent compounds, microdosing technologies for ultra‑low‑dose studies, and integrated clinical‑to‑commercial supply networks. It also illustrates why continuity across formulation, sterile and oral solid dose manufacturing, packaging, quality, and global distribution is essential to avoid fragmentation and protect scarce patient enrolment. Ultimately, the article frames rare disease development as a test of the industry’s ability to build precise, resilient, and globally connected infrastructure — systems designed not for mass‑market efficiency, but for the small populations whose lives depend on therapies that cannot be served by scale alone.